KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Deferred Tax Assets: 2010-2014

Historic Current Deferred Tax Assets for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Dec 2014 value amounting to $31.2 million.

  • Biomarin Pharmaceutical's Current Deferred Tax Assets rose 5.94% to $30.9 million in Q3 2015 from the same period last year, while for Sep 2015 it was $30.9 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of $31.2 million for FY2014, which is 2.09% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Current Deferred Tax Assets stood at $31.2 million for FY2014, which was up 2.09% from $30.6 million recorded in FY2013.
  • Biomarin Pharmaceutical's 5-year Current Deferred Tax Assets high stood at $32.4 million for FY2012, and its period low was $16.7 million during FY2010.
  • For the 3-year period, Biomarin Pharmaceutical's Current Deferred Tax Assets averaged around $31.4 million, with its median value being $31.2 million (2014).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Current Deferred Tax Assets soared by 53.24% in 2012 and then decreased by 5.55% in 2013.
  • Biomarin Pharmaceutical's Current Deferred Tax Assets (Yearly) stood at $16.7 million in 2010, then grew by 26.76% to $21.1 million in 2011, then surged by 53.24% to $32.4 million in 2012, then decreased by 5.55% to $30.6 million in 2013, then climbed by 2.09% to $31.2 million in 2014.